CD47 and cancer: In coculture assays, only osimertinib rendered the cancer cells more vulnerable to the anti-CD47 antibody, whereas neither erlotinib or gefitinib inhibited cell growth as single agents nor in concert with CD47 blockade (Figure 3E and Supplemental Figure 8D).